Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 1:13:21-32.
doi: 10.2147/DNND.S384038. eCollection 2023.

Neuroimaging Correlates of Patient-Reported Outcomes in Multiple Sclerosis

Dejan Jakimovski #  1 , Taylor R Wicks #  1 , Niels Bergsland  1   2 , Michael G Dwyer  1 , Bianca Weinstock-Guttman  3 , Robert Zivadinov  1   4
Affiliations

Neuroimaging Correlates of Patient-Reported Outcomes in Multiple Sclerosis

Dejan Jakimovski et al. Degener Neurol Neuromuscul Dis. .

Abstract

Background: Patient-reported outcomes (PROs) are increasingly associated with concurrent and future impairments in persons with multiple sclerosis (pwMS). The structural and pathological relationships with PROs in pwMS have not been elucidated.

Methods: One hundred and forty-two pwMS and 47 healthy controls (HCs) were scanned using 3T MRI and completed a PRO questionnaire named Lifeware® that outlines the physical and psychosocial abilities. Beck's Depression Inventory (BDI) assessed levels of depression. T1- and T2-lesion volume, volumes of the whole brain (WBV), gray matter (GMV), white matter (WMV) and lateral ventricle (LVV) were derived using JIM and SIENAX software. Additional deep GM (DGMV) and nuclei-specific volumes of the thalamus, caudate, globus pallidus, putamen, and hippocampus were calculated using FIRST. Ordinal regression models adjusted for age and depression and mediation analyses were used.

Results: When compared to HCs, pwMS reported significantly greater limitations in mobility domains, including standing up from low seat (p < 0.001), climbing flight of stairs (p < 0.001), lower limb limitation (p < 0.001), limitations in bladder continence (p = 0.001) and fatigability (p < 0.001). Patient-reported limitations related to lower extremity function were explained by age, BDI, and all DGM nuclei volumes (p < 0.029). No such relationships were seen in the HCs. Fatiguability and the extent of life satisfaction were only related to depression (BDI p < 0.001) and not associated with any MRI-based outcomes. Most relationships between structural pathology and PROs were mediated by BDI scores (p < 0.001). In the pwMS group, there were no significant differences in any MRI-based brain volumes between the levels of reported life satisfaction.

Conclusion: PRO measures of lower extremity limitations were associated with DGM structures and DGM-specific nuclei. These findings promote the relevance of measuring DGM structures as measures directly related to subjective well-being and walking limitations. Depression is a significant mediator of PROs and in particular of life satisfaction.

Keywords: MRI; deep gray matter; multiple sclerosis; patient-reported outcomes.

PubMed Disclaimer

Conflict of interest statement

Dejan Jakimovski serves as Associate Editor of Clinical Neurology and Neurosurgery and compensated by Elsevier B.V. Taylor Wicks and Niels Bergsland have nothing to disclose. Michael G. Dwyer received compensation from Keystone Heart for consultant fees. He received financial support for research activities from Bristol Myers Squibb, Novartis, Merck Serono, Mapi Pharma, Keystone Heart, Protembis and V-WAVE Medical. Bianca Weinstock-Guttman received honoraria as a speaker and/or as a consultant for Biogen Idec, Teva Pharmaceuticals, EMD Serono, Genzyme, Sanofi, Genentech, Novartis, Celgene/BMS, Janssen, Labcorp, TG therapeutics, and Horizon. Dr Weinstock-Guttman received research funds from Biogen Idec, EMD Serono, Genzyme, Genentech, Sanofi, Novartis. Robert Zivadinov has received personal compensation from Bristol Myers Squibb, EMD Serono, Sanofi, Protembis, Janssen, 415 Capital, and Novartis for speaking and consultant fees. He received financial support for research activities from Sanofi, Novartis, Bristol Myers Squibb, Octave, Mapi Pharma, CorEvitas, Protembis and V-WAVE Medical. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
The mediating effect of depression on the relationship between DGM volume with limitations in “climbing stairs” (A) and life satisfaction (B).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. Lancet. 2018;391(10130):1622–1636. doi:10.1016/S0140-6736(18)30481-1 - DOI - PubMed
    1. Young CA, Mills R, Rog D, et al. Quality of life in multiple sclerosis is dominated by fatigue, disability and self-efficacy. J Neurol Sci. 2021;426:117437. doi:10.1016/j.jns.2021.117437 - DOI - PubMed
    1. Lakin L, Davis BE, Binns CC, Currie KM, Rensel MR. Comprehensive approach to management of multiple sclerosis: addressing invisible symptoms-a narrative review. Neurol Ther. 2021;10:75–98. doi:10.1007/s40120-021-00239-2 - DOI - PMC - PubMed
    1. Hanna M, Strober LB. Anxiety and depression in Multiple Sclerosis (MS): antecedents, consequences, and differential impact on well-being and quality of life. Mult Scler Relat Disord. 2020;44:102261. doi:10.1016/j.msard.2020.102261 - DOI - PMC - PubMed
    1. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444–1452. doi:10.1212/WNL.33.11.1444 - DOI - PubMed